.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
QuintilesIMS
Citi
Dow
UBS
McKinsey
Cantor Fitzgerald
AstraZeneca
Healthtrust
Baxter

Generated: December 12, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,399,496

« Back to Dashboard

Claims for Patent: 8,399,496

Title:Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
Inventor(s): Montgomery; Alan Bruce (Seattle, WA), Keller; Manfred (Munchen, DE), Lintz; Frank-Christophe (Starnberg, DE)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/229,425
Patent Claims: 1. An inhalable composition comprising astreonam lysinate and a pharmaceutically acceptable diluent.

2. A method for administering by inhalation aztreonam lysinate comprising administering a composition comprising aztreonam lysinate and a pharmaceutically acceptable diluent.

3. The method according to claim 2, wherein the diluent is saline.

4. The method according to claim 2, wherein said composition comprises from about 1 to about 250 mg of aztreonam lysinate dissolved in about 1 to about 5 mL of saline solution containing from about 0.1 to about 0.9%, w/v, of sodium chloride.

5. The method according to claim 2, wherein said composition is delivered by a nebulizer.

6. The method according to claim 5, wherein said nebulizer is an atomizing jet, ultrasonic, electronic or vibrating porous plate nebulizer.

7. The method according to claim 2, wherein said composition consists of 75 mg of aztreonam and 47 mg of lysine per 1 mL of saline.

8. A method for improving pulmonary function in a patient with cystic fibrosis, said method comprising administering by inhalation aztreonam lysinate to said patient.

9. The method according to claim 8, wherein said step of administering comprises administering a composition comprising aztreonam lysinate and a pharmaceutically acceptable diluent.

10. The method according to claim 9, wherein the diluent is saline.

11. The method according to claim 9, wherein said composition comprises from about 1 to about 250 mg of aztreonam lysinate dissolved in about 1 to about 5 mL of saline solution containing from about 0.1 to about 0.9%, w/v, of sodium chloride.

12. The method according to claim 9, wherein said composition is delivered by a nebulizer.

13. The method according to claim 12, wherein said nebulizer is an atomizing jet, ultrasonic, electronic or vibrating porous plate nebulizer.

14. The method according to claim 11, wherein said composition consists of 75 mg of aztreonam and 47 mg of lysine per 1 mL of saline.

15. A method for treating an infection caused by gram-negative bacteria in a patient with cystic fibrosis, said method comprising administering by inhalation an aztreonam lysinate composition to said patient, wherein said composition comprises from about 1 to about 250 mg of aztreonam lysinate dissolved in about 1 to about 5 mL of saline solution containing from about 0.1 to about 0.9%. w/v, of sodium chloride.

16. The method according to claim 15, wherein said composition consists of sodium chloride composition consists of 75 mg of aztreonam and 47 mg of lysine per 1 mL of saline.

17. A method according to claim 15, wherein said composition is delivered by a nebulizer.

18. The method according to claim 17, wherein said nebulizer is an atomizing jet, ultrasonic, electronic or vibrating porous plate nebulizer.

19. A method for treating an infection caused by gram-negative bacteria in a patient with bronchiectasis, said method comprising administering by inhalation aztreonam lysinate to said patient

20. The method according to claim 19, wherein said step of administering comprises administering a composition comprising aztreonam lysinate and a pharmaceutically acceptable diluent.

21. The method according to claim 20, wherein said composition comprises from about 1 to about 250 mg of aztreonam lysinate dissolved in about 1 to about 5 mL of saline solution containing from about 0.1 to about 0.9%, w/v, of sodium chloride.

22. The method according to claim 21, wherein said composition is delivered by a nebulizer.

23. The method according to claim 22, wherein said nebulizer is an atomizing jet, ultrasonic, electronic, or vibrating porous plate nebulizer.

24. The method according to claim 21, wherein said composition consists of 75 mg of aztreonam and 47 mg of lysine per 1 mL of saline.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Julphar
Accenture
Colorcon
McKinsey
Teva
Daiichi Sankyo
Chinese Patent Office
Moodys
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot